Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 2, 2014, Pages 303-311

  Inoue, Masaharu ^a   Koga, Fumitaka ^a   Yoshida, Soichiro ^a   Tamura, Tomoki ^b   Fujii, Yasuhisa ^a   Ito, Eisaku ^b   Kihara, Kazunori ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; DISEASES; MULTIVARIANT ANALYSIS; MUSCLE; PATIENT MONITORING; PLATINUM COMPOUNDS; TUMORS;

CHEMORADIATION THERAPIES; CONCURRENT CISPLATIN; IMMUNOHISTOCHEMICAL ANALYSIS; INDEPENDENT PREDICTORS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PELVIC LYMPH NODES; TRANSURETHRAL RESECTIONS;

PATIENT TREATMENT;

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; RADIOSENSITIZING AGENT; TUMOR PROTEIN;

AGED; ARTICLE; BLADDER PRESERVATION; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTECTOMY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; ORGAN PRESERVATION; PELVIS LYMPH NODE; POOR GENERAL CONDITION; PROSPECTIVE STUDY; SELECTIVE BLADDER SPARING APPROACH; SURGICAL APPROACH; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROLOGICAL PROCEDURE; BLADDER; CONSERVATIVE TREATMENT; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AGED; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; RADIATION-SENSITIZING AGENTS; RECEPTOR, ERBB-2; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84908206009     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.05.043     Document Type: Article

References (30)

1. S.M. Gilbert, D.P. Wood, and R.L. Dunn Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI) Cancer 109 2007 1756 1762
2. C. Rodel, C. Weiss, and R. Sauer Trimodality treatment and selective organ preservation for bladder cancer J Clin Oncol 24 2006 5536 5544
3. W.U. Shipley, D.S. Kaufman, and W.J. Tester Overview of bladder cancer trials in the Radiation Therapy Oncology Group Cancer 97 2003 2115 2119
4. J.A. Estathiou, D.Y. Spiegel, and W.U. Sipley Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience Eur Urol 61 2012 705 711
5. M. Hausset, C. Maulard, and Y. Chretien Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study J Clin Oncol 11 1993 2150 2157
6. A.L. Zietman, D. Sacco, and U. Skowronski Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Result of a urodynamic and quality of life study on long-term survivors J Urol 170 2003 1772 1776
7. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
8. F. Koga, S. Yoshida, and S. Kawakami Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis Urology 72 2008 384 388
9. F. Koga, Y. Fujii, and H. Masuda Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches BJU Int 110 2012 E203 E208
10. F. Koga, N. Numao, and K. Saito Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients Urol Oncol 31 2013 1270 1275
11. F.S. Krause, B. Walter, and O.J. Ott 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment Anticancer Res 31 2011 985 990
12. M.D. Marmor, K.B. Skaria, and Y. Yarden Signal transduction and oncogenesis by ErbB/HER receptors Int J Radiat Oncol Biol Phys 58 2004 903 913
13. S.C. Formenti, D. Spicer, and K. Skinner Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer Int J Radiat Oncol Biol Phys 52 2002 397 405
14. M. Akamatsu, T. Matsumoto, and K. Oka c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma Int J Radiat Oncol Biol Phys 57 2003 1323 1327
15. S. Kuyama, K. Hotta, and M. Tabata Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer J Thorac Oncol 3 2008 477 482
16. S. Kruger, G. Weitsch, and H. Buttner HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications Int J Cancer 102 2002 514 518
17. A. Chakravarti, K. Winter, and C.L. Wu Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2005 309 317
18. W. Choi, S. Porten, and S. Kim Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
19. Koga F, Yoshida S, Tatokoro M, et al. ERBB 2 and NF?B overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One 2011; 6: e27616.
20. F. Koga, K. Kihara, and Y. Fujii Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study BJU Int 104 2009 189 194
21. F. Koga, K. Kihara, and S. Yoshida Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients BJU Int 109 2011 860 866
22. L.H. Sobin, and C. Wittekind Classification of Malignant Tumours 6th ed 2002 Wiley-Liss New York
23. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
24. M.A. Tunio, A. Hashmi, and A. Qayyum Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience Int J Radiat Oncol Biol Phys 82 2012 e457 462
25. F. Koga, and K. Kihara Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review Int J Urol 19 2012 388 401
26. S. Yoshida, F. Koga, and M. Tatokoro Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy Cell Cycle 10 2011 4291 4299
27. K. Jhaveri, S. Chandarlapaty, and D. Lake A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer Clin Breast Cancer 14 2013 154 160
28. M.A. Socinski, J. Goldman, and I. EI-Hariry A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer Clin Cancer Res 19 2013 3068 3077
29. F. Koga, K. Kihara, and L. Neckers Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90 Anticancer Res 29 2009 797 807
30. J. Trepel, M. Mollapour, and G. Giaccone Targeting the dynamic HSP90 complex in cancer Nat Rev Cancer 10 2010 537 549